Causes of Visual Loss in Retinal Disease

NCT01613963 | Unknown

• 1 other identifier: 12DEV0010
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 2

Brief Summary

This is a study of visual outcomes in retinal disease that seeks to identify the causes of visual loss. This data will be used to predict which patients are at risk of losing vision and how they can be better treated.

Conditions

Uveitis; Scleritis

Keywords

Uveitis; Scleritis

Outcome Measures

Primary Outcomes (1)

• Visual acuity at 5 years

  Best-corrected visual acuity at 5 years

  5 years

Secondary Outcomes (16)

• Visual acuity at 10 years

  10 years

• Source of referral

  Baseline

• Laterality

  Baseline

• Anatomical diagnosis

  Baseline

• Aetiological diagnosis

  Baseline

Study Arms (1)

Patients with ocular inflammation

Patients with ocular inflammation

Drug: Immunosuppressive Agents

Interventions

Immunosuppressive Agents DRUG

Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs

Also known as: Prednisolone, Azathioprine, Methotrexate, Mycophenolate mofetil, Cyclosporine A, Infliximab, Adalimumab, Etanercept, Rituximab

Patients with ocular inflammation

Eligibility Criteria

• Age: 16 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with ocular inflammation

You may qualify if:

• patients with a diagnosis of ocular inflammation
• patients with at least 6 months of follow-up

You may not qualify if:

• patients without a diagnosis of ocular inflammation
• patients with less than 6 months of follow-up

Sponsors & Collaborators

• Royal Surrey County Hospital NHS Foundation Trust: lead

Study Sites (2)

Moorfields Eye Hospital

London, London, EC1V 2PD, United Kingdom

Location

Royal Surrey County Hospital

Guildford, UK, GU2 7XX, United Kingdom

Location

MeSH Terms

Conditions

Uveitis; Scleritis

Interventions

Immunosuppressive Agents; Prednisolone; Azathioprine; Methotrexate; Mycophenolic Acid; Cyclosporine; Infliximab; Adalimumab; Etanercept; Rituximab

Condition Hierarchy (Ancestors)

Uveal Diseases; Eye Diseases; Scleral Diseases

Intervention Hierarchy (Ancestors)

Immunologic Factors; Physiological Effects of Drugs; Pharmacologic Actions; Chemical Actions and Uses; Pregnadienetriols; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Thionucleosides; Sulfur Compounds; Organic Chemicals; Mercaptopurine; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Aminopterin; Pterins; Pteridines; Caproates; Acids, Acyclic; Carboxylic Acids; Fatty Acids; Lipids; Cyclosporins; Peptides, Cyclic; Macrocyclic Compounds; Peptides; Amino Acids, Peptides, and Proteins; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Serum Globulins; Globulins; Antibodies, Monoclonal, Humanized; Immunoglobulin Fc Fragments; Immunoglobulin Fragments; Peptide Fragments; Immunoglobulin Constant Regions; Receptors, Tumor Necrosis Factor; Receptors, Cytokine; Receptors, Immunologic; Receptors, Cell Surface; Membrane Proteins; Antibodies, Monoclonal, Murine-Derived

Study Officials

• Simon RJ Taylor, PhD FRCOphth

  Royal Surrey County Hospital NHS Foundation Trust

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Senior Lecturer & Consultant Ophthalmic Surgeon

Study Record Dates

• First Submitted: May 29, 2012
• First Posted: June 7, 2012
• Study Start: May 1, 2012
• Primary Completion: December 1, 2012
• Study Completion: December 1, 2012
• Last Updated: June 7, 2012

Record last verified: 2012-06

Locations

GB (2)